Integris Medtech Files DRHP with SEBI for IPO comprising ₹925 Crore Fresh Issue and 2.17 Crore-Share OFS

New Delhi, October 10, 2025: Integris Medtech Limited has announced that it has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI). The proposed IPO aims to raise up to ₹9,250 million (₹925 crore) through a fresh issue of shares and includes an Offer for Sale (OFS) of up to 21,674,531 equity shares of face value ₹1 each. The OFS will involve share sales by the company’s promoters, including:

• Evercure Holdings Pte. Ltd. – 15,174,251 shares
• Gurmit Singh Chugh – 3,250,140 shares
• Punita Sharma – 3,250,140 shares

Integris Medtech Limited is an Indian company that provides medical devices and laboratory solutions. It was established in 2008 and is headquartered in New Delhi.

Integris Medtech Repayment and Prepayment of Borrowings Primary Fundraising Motive

The company will use the proceeds from the IPO mainly for repaying or prepaying certain borrowings availed by its subsidiaries and step-down subsidiaries such as Translumina Therapeutics Pvt. Ltd., Transhealth Pvt. Ltd., HaleMed Medical Pvt. Ltd., CPC Diagnostics Pvt. Ltd., and Chemopharm Group. The company will use the remaining amount for general corporate purposes.

Integris Medtech Revenue At ₹19,024.66 Million While PAT At ₹1,178.44 Million

In FY25, Integris Medtech Limited delivered strong financial results. Revenue from operations (restated) rose 13.2% year-on-year to ₹19,024.66 million, compared to ₹16,812.24 million in FY24. On a pro forma basis, revenue stood at ₹23,328.12 million, reflecting a 14.0% increase from ₹20,465.37 million. EBITDA (restated) climbed to ₹3,102.87 million, while profit after tax (restated) increased 10.9% to ₹1,178.44 million. According to a Frost & Sullivan report, Integris ranks among India’s top two MedTech companies by operating revenue for FY25.

REF: https://nsearchives.nseindia.com/corporate/Registration_10102025124732_DRHP.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations